[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054012":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":34,"responsibleParty":52,"collaborators":20,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":20,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":37,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin Treatment","EXPERIMENTAL","850mg PO daily",[13],"Drug: Metformin",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Metformin","Given PO",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Oliver Eng, MD","Chao Family Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Chao Family Comprehensive Cancer Center University of California, Irvine","CONTACT","1-877-827-8839","ucstudy@uci.edu",{"name":33,"role":29,"phone":20,"phoneExt":20,"email":20},"University of California Irvine Medical",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Chao Family Comprehensive Cancer Center, University of California, Irvine","RECRUITING","Orange","California","92868","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.85311,33.78779,{"lat":47,"lon":46},[50],{"name":23,"role":29,"phone":51,"phoneExt":20,"email":31},"877-827-8839",{"type":25,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Oliver Eng","Associate Professor","100054012","phase-2-metformin-in-pseudomyxoma-peritonei-secondary-to-appendiceal-mucinous-neoplasms-100054012",false,"NCT07693452","Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms","Key Inclusion Criteria (complete details available in protocol):\n\n* Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent\u002Frefractory disease s\u002Fp cytoreductive surgery(CRS)\u002Fhyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS\u002FHIPEC\n* Age ≥18 years\n* ECOG performance status ≤2\n\nKey Exclusion Criteria (complete details available in protocol):\n\n* Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS\u002FHIPEC\n* Patients currently taking metformin for another medical indication\n* Patients with a prior adverse event to administration of metformin","ALL","18 Years",{"count":65,"type":66},15,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).",[72,73],"Appendiceal Mucinous Neoplasm","Pseudomyxoma Peritonei",[72,73,75,76,77,17],"Pseudomyxoma Peritoneal","PMP","AMNs","2026-07-09",{"date":80,"type":81},"2026-07-13","ACTUAL",{"date":83,"type":81},"2026-06-18",{"date":85,"type":66},"2029-07",{"name":5,"class":6},1]